6 citations
,
October 2015 in “Journal of Medicinal Chemistry” The document confirms the structures of major metabolites of the CRTh2 antagonist Setipiprant and identifies minor metabolites.
4 citations
,
February 2019 in “PubMed” Clascoterone may be an effective topical treatment for hair loss.
December 2023 in “Journal of Medicinal Chemistry” A new topical treatment for hair loss shows strong hair growth effects with low toxicity.
October 2023 in “Scientific reports” Dexamethasone affects hair growth by altering levels of proteins that either promote or inhibit hair follicle growth.
April 2024 in “Expert opinion on emerging drugs”
32 citations
,
December 2003 in “Planta” Hypaphorine from a fungus changes the internal structure of Eucalyptus root hairs, stopping their growth.
9 citations
,
November 2014 in “Experimental Dermatology” PTHRP agonists can stimulate hair growth, especially in damaged follicles, while antagonists may initially increase growth but ultimately inhibit it.
May 2024 in “Journal of molecular structure” A new compound, 3a, effectively fights prostate cancer better than finasteride.
June 2010 in “Melanoma research” LDE225 is a promising skin-applied treatment for basal cell carcinoma with good skin penetration and effectiveness.
14 citations
,
November 2007 in “Bioorganic & Medicinal Chemistry Letters” The compound (1R,2S)-4-(2-Cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile can stimulate hair growth and reduce oil production when applied topically.
9 citations
,
April 2021 in “Expert opinion on pharmacotherapy” Clascoterone is a new, effective, and safe acne treatment without systemic side effects.
6 citations
,
February 2023 in “Journal of nanobiotechnology” The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.
5 citations
,
December 2011 in “Drug Research” CB-03-01 is a promising skin cream for treating hormone-related skin problems without causing harmful body-wide effects.
September 2016 in “Journal of Investigative Dermatology” DHT reduces a cell's ability to promote hair growth, while 3D culture without DHT improves it.
23 citations
,
October 2008 in “Journal of medicinal chemistry” PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.
14 citations
,
February 1994 in “Tetrahedron Letters” Adding cerium(III) chloride to Grignard reagents improves the making of compounds that could treat prostate issues and hair loss.
3 citations
,
September 2017 in “Bioorganic & medicinal chemistry letters” New compounds were made that are promising for prostate cancer therapy.
24 citations
,
November 2017 in “Prostaglandins & Other Lipid Mediators” CRTH2 antagonists might be useful for treating many conditions because they play a role in immune and inflammation responses.
52 citations
,
March 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
August 1994 in “Drugs & Therapy Perspectives” The document concludes that H2-antagonists and proton pump inhibitors are highly effective for ulcers, eradicating Helicobacter pylori is important to prevent recurrence, and misoprostol helps with NSAID-related ulcers.
71 citations
,
February 2000 in “Endocrinology and metabolism/American journal of physiology: endocrinology and metabolism” Estradiol stops hair growth in mice, but an antagonist can reverse this effect.
January 2017 in “Journal of Investigative Dermatology Symposium Proceedings” The 2015 Hair Research Congress concluded that stem cells, maraviroc, and simvastatin could potentially treat Alopecia Areata, topical minoxidil, finasteride, and steroids could treat Frontal Fibrosing Alopecia, and PTGDR2 antagonists could also treat alopecia. They also found that low-level light therapy could help with hair loss, a robotic device could assist in hair extraction, and nutrition could aid hair growth. They suggested that Alopecia Areata is an inflammatory disorder, not a single disease, indicating a need for personalized treatments.
6 citations
,
January 1998 in “Journal of Investigative Dermatology” Estrogen receptors may not affect mouse hair growth as previously thought, and oxybenzone in sunscreen is stable in sunlight.
February 2024 in “Practical Diabetes” Spironolactone helps reduce hospital visits and death from heart issues, lowers blood pressure, but has unclear effects on heart failure with normal heart pump function and can cause high potassium and breast enlargement in men.
65 citations
,
June 2003 in “EMBO journal” Noggin overexpression delays eyelid opening by affecting cell death and skin cell development.
4 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Doctors are prescribing spironolactone more often to treat acne and skin conditions in teenagers, and it seems safe and well-tolerated.
December 2021 in “Journal of pharmaceutical research international” Spironolactone may be effective for acne and other skin conditions and could be used more in treatment.
3 citations
,
June 1983 in “Archives of Dermatology” Aminopterin effectively improves skin conditions but has toxic side effects that need careful monitoring.
July 2019 in “Journal of the European Academy of Dermatology and Venereology” Some eczema treatments may cause conjunctivitis, many people have sensitive eyes, air pollution can increase skin wrinkles, hair loss medication does not affect sexual function, and dermatologists can help identify torture signs on refugees' skin.
67 citations
,
February 2006 in “Annals of Oncology” Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.